Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

medRxiv : the preprint server for health sciences·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes.

Blood advances·2026
Same author

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Blood neoplasia·2026

Related Experiment Video

Updated: Dec 27, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K

Targeting TP53 Mutations in Myelodysplastic Syndromes.

Anthony M Hunter1, David A Sallman2

  • 1Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, GME office, 12902 USF Magnolia Drive, Tampa, FL 33612, USA; University of South Florida, Morsani College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA.

Hematology/Oncology Clinics of North America
|February 25, 2020
PubMed
Summary

TP53 mutations significantly worsen outcomes for myelodysplastic syndromes (MDS) patients. Novel therapies targeting mutant TP53 or using immunotherapy show promise for this challenging patient group.

Keywords:
Myelodysplastic syndromeTP53TP53 mutant MDSTherapy-related myelodysplastic syndrome

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.2K

Related Experiment Videos

Last Updated: Dec 27, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

12.2K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Mutations in the TP53 gene are found in approximately 20% of myelodysplastic syndromes (MDS) cases.
  • TP53 mutations are more prevalent in patients with complex karyotypes and therapy-related MDS.
  • TP53 mutations are a significant negative prognostic factor in MDS, associated with poor outcomes across all current treatments.

Purpose of the Study:

  • To highlight the prognostic impact of TP53 mutations in MDS.
  • To review current treatment outcomes for MDS patients with TP53 mutations.
  • To identify promising novel therapeutic strategies for this subgroup.

Main Methods:

  • Literature review of studies investigating TP53 mutations in MDS.
  • Analysis of treatment outcomes based on TP53 mutation status.
  • Evaluation of emerging therapeutic approaches targeting TP53 mutations.

Main Results:

  • MDS patients with TP53 mutations demonstrate inferior survival and response rates.
  • Hypomethylating agents are the current standard frontline therapy but yield suboptimal results.
  • Allogeneic hematopoietic stem cell transplant offers a potential cure but has poor outcomes in this cohort.

Conclusions:

  • TP53 mutations confer a poor prognosis in MDS, necessitating new treatment paradigms.
  • Targeted therapies directly addressing mutant TP53 protein and immunotherapies represent the most promising avenues for improving outcomes.
  • Further research is crucial to develop effective treatments for MDS patients with TP53 alterations.